FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors reported to be useful for the treatment of ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.